Clinicians

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved

Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.

For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door

Diphtheria Came Back. Remote Communities Are Carrying the Cost.

Gonorrhoea Is Not Disappearing. Too Many Systems Are Failing to See It.

Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.

The Biomarker Test Cannot Wait Until Relapse

Cancer Treatment Is an Endurance Event. Stop Waiting for Patients to Lose Function.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
